The latest updates on Orthofix Medical center on a reset in price targets into a tighter US$9 to US$10 range. Analysts link these revised targets to Q3 revenue, adjusted EBITDA and cash flow shortfalls, along with a reassessment of how much execution risk to factor into their models. As you read on, you will see how to interpret this evolving Orthofix Medical story and what to watch as the narrative develops. Analyst Price Targets don't always capture the full story. Head over to our Company...
Orthofix (OFIX) delivered earnings and revenue surprises of +63.64% and -1.25%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Orthofix Medical recently saw its analyst price target move from US$15 to US$13, a reset that anchors the latest round of valuation work on the stock. Analysts link this change to updated views on revenue, cash generation and the impact of the MDR transition, even as many maintain a constructive long-term stance. Read on to see what is driving the shift in targets and how you can track the evolving Orthofix Medical story from here. Analyst Price Targets don't always capture the full story...
This is the newest page. Registered accounts read further back.